Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. - Wikidata - wikimedia - TriplyDB

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

http://www.wikidata.org/entity/Q37368203

about

Clinical impacts of mesothelin expression in gastrointestinal carcinomas Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Toxin-based therapeutic approaches Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer Advances in anticancer immunotoxin therapy Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.Discovery of mesothelin and exploiting it as a target for immunotherapy.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy What's the place of immunotherapy in malignant mesothelioma treatments?Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.Novel systemic therapy against malignant pleural mesothelioma.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.Advances in the management of peritoneal mesothelioma ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.Inhibition of mesothelin as a novel strategy for targeting cancer cells.Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.New roads open up for implementing immunotherapy in mesothelioma.Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers.In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.

P2860

Q26748680-D46E217C-39AE-4197-A277-FD76CB34B238 Q26778759-C135A90E-9E69-43DF-AB8B-00E9178F81D0 Q26853171-FF57DE7C-DBCA-439B-B420-C01F850AD4F7 Q27013664-F754F4B5-0762-4675-8F1D-FE1EFDC79120 Q27015134-D0348C1F-0C89-455A-8AFA-4DD32BFD8B83 Q28077270-0E6D477C-FD12-4AD3-88A9-1451722FD676 Q28085551-0E650787-FE29-4E41-8FB4-044642B1E65B Q28266122-031B1F54-056B-4F54-B04C-38807256995F Q28392105-111C3362-4C6F-41DB-A014-35C345AD3436 Q28395597-459F49DE-35CD-4580-9B31-4E10ABC2AD06 Q28546010-A55760E4-98AB-4B5E-B458-84DD5D52D555 Q28553712-AF2D11DD-6703-4054-9356-B30D35ECEBC3 Q33652098-7F53E9A4-BF47-4E19-8896-D88136C1A314 Q33767727-07566DDA-89A1-4220-B776-8F2400861963 Q33772688-BA89F312-4987-4FF5-BE18-AAD9336958F3 Q33779122-F3832ED1-B12E-407E-BE39-9862475A6EBE Q33781142-97A2BADA-6273-400E-A121-BA963BBE0582 Q33816551-5904A5FA-CF22-48C8-8248-3F30D6A04940 Q33864348-145CEA60-84EA-46E0-B993-85B4FC196EFB Q33890499-55C5AC07-51F1-45CB-8D9E-9E0CDFFCDAED Q33932779-D7605995-35F2-41BD-B760-5B19E41332B4 Q34080906-692357E6-819E-46D8-91A4-3F0FE3D140D0 Q34137322-A40E4946-8C40-4E93-AAE6-033170FE4F57 Q34144923-210BA613-611B-41D0-AC9E-D60CF8D9C6FB Q34224746-8E53C4DC-4D59-42F7-8DE1-77E62C2376DF Q34323838-3CDDEC08-61AA-43DA-B550-4B336E22E5C4 Q34331993-9890827E-026A-45C3-AE9F-B2131B8CE678 Q34459015-96D502A2-3F26-477A-8EAA-A41CFBCF235B Q34575951-1321FBC5-BA04-407C-86E1-7D2CB746CA8C Q34676443-612587D2-9B1A-4C31-A47A-F60705417B49 Q34703865-85C7AD36-C688-49F2-A9B3-CDB39FB613B8 Q34752012-963CE57F-A66E-4F61-8A91-AC4BD66BC20E Q34771909-9DF1930B-61B2-4AE5-8812-AD917F85394F Q34804520-83DA37D2-9B1B-4261-A736-F0DF12264026 Q34923432-917CE4D2-37B2-4206-8E19-3E7914411BA6 Q34984956-42B0A62C-99B0-4502-914F-047E781603F9 Q35018336-74C4BCDE-95FA-49DA-AB33-56D0A7028A94 Q35023967-CDC8BAE4-B451-496A-B90F-13DBCE60943C Q35042668-267C8975-06E6-4645-8947-9D4C5B47A49C Q35049589-E06FD2E4-5B6E-4283-8581-8E82E1179557

P2860

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

http://www.wikidata.org/entity/Q37368203

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@en

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@nl

type

label

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@en

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@nl

prefLabel

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@en

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@nl

P1433

Q37368203-89B514C9-6A21-4510-AFBE-1175B40E189E

P1476

Q37368203-602C5D59-9F2A-412F-B5EC-9A3C1D52767A

P2093

Q37368203-1593E485-3248-4BE2-8587-1C79F66BC78D

Q37368203-7D2BC76C-92D3-4386-A34A-F9B62EE2A055

Q37368203-EB481D8B-5FBD-4955-A4CF-3E66FBEB992D

Q37368203-F2CB929D-A1D5-4C07-AA56-22109ABB598E

P2860

Q37368203-08B56DAA-0E08-48BC-A49C-16BF1C54F4F8

Q37368203-0D165073-61F7-495E-B68B-1D9C4AD5959D

Q37368203-0E542CAE-F489-413D-8853-9A03B9644FC1

Q37368203-0F900E91-3245-438D-90AA-FD12088EEC59

Q37368203-16A5ED45-2B06-4CF6-925F-AC88127A6990

Q37368203-1799BD32-25AB-429B-B849-C8BBCF8E6307

Q37368203-1C44A2D3-DD9D-4AB1-BF57-F2A7B2BF81AC

Q37368203-3F4A78EE-2F48-48FD-BC93-A2B35A03BCF5

Q37368203-564EFA3E-7196-44BF-90CA-8365A88A2E22

Q37368203-5A6AF7A1-A167-47FB-9702-3D897ACE0E6A

P304

Q37368203-7458ABDA-210E-4504-9480-FFF2DFB7A048

P31

Q37368203-269C26E6-92FF-4085-B3CD-41419EB15330

P356

Q37368203-49E53339-E473-4816-A795-A53EE1226A4C

P407

Q37368203-6C89AC73-5D0C-438A-A129-5D385AC0F007

P433

Q37368203-0B3A316E-5875-40FC-A245-4C026229AD5F

P478

Q37368203-D941CE32-31AF-44FD-9166-BC256A919040

P577

Q37368203-463B39D7-9D81-456E-9448-24B0F24D091D

P698

Q37368203-01B6D6E3-60B9-4312-9F07-453A1DDD663A

P921

Q37368203-0E6EDEE5-CD74-4363-BE07-C9CE29CFA137

P932

Q37368203-56C5770A-98E4-4029-AAB5-5EEFBAF5296F

P356

1078-0432.CCR-09-0062

P1433

Clinical Cancer Research

P1476

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

@en

P2093

David J Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Raffit Hassan

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

Mesothelin: a new target for immunotherapy

Improving antibody affinity by mimicking somatic hypermutation in vitro.

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

Immunotoxin treatment of cancer.

P304

5274-5279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0062

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19671873

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2754261

http://www.w3.org/2001/XMLSchema#string